2,3,4-Tri-O-benzoyl-L-fucopyranose - CAS 485821-70-3
Category:
Carbohydrates
Product Name:
2,3,4-Tri-O-benzoyl-L-fucopyranose
CAS Number:
485821-70-3
Molecular Weight:
476.47
Molecular Formula:
C27H24O8
COA:
Inquire
MSDS:
Inquire
Structure:
Monosaccharides
Chemical Structure
CAS 485821-70-3 2,3,4-Tri-O-benzoyl-L-fucopyranose

Related Monosaccharides Products


Reference Reading


1.Prevalence of self-injury performed by adolescents aged 16-19 years.
Pawłowska B1, Potembska E2, Zygo M3, Olajossy M1, Dziurzyńska E4. Psychiatr Pol. 2016;50(1):29-42. doi: 10.12740/PP/36501.
OBJECTIVES: The aim of the study was to assess the prevalence of self-injury among adolescents aged 16-19 years and to indicate demographic variable, selected environmental variables and risky behaviours coexisting with performing self-injuries by the respondents.
2.Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study.
Beesley VL1, Wockner LF2, O'Rourke P2, Janda M3, Goldstein D4,5, Gooden H6, Merrett ND7,8, O'Connell DL9, Rowlands IJ10, Wyld DK11,12, Neale RE2. Support Care Cancer. 2016 Apr 16. [Epub ahead of print]
PURPOSE: This study aims to determine if the supportive care needs of people with pancreatic cancer change over time and identify the factors associated with current and future unmet needs.
3.Involuntary psychiatric holds - the structure of admissions on the example of Institute of Psychiatry and Neurology in Warsaw.
Markiewicz I1, Heitzman J1, Gardyńska-Ziemba E2. Psychiatr Pol. 2016;50(1):7-18. doi: 10.12740/PP/33336.
OBJECTIVES: The aim of the study was to analyse the structure of involuntary psychiatric holds in Institute of Psychiatry and Neurology in Warsaw, throughout the year. Our research interests included socio-demographic profiles of the patients, time of admissions (time of a day/night/ season), type of diagnoses at admission and suicide attempts preceding the admission. We also analysed the normative aspect of involuntary admissions, i.e. which Articles of the Polish Mental Health Act constituted the basis for these patients admission, and if the choice of articles was justifiable by a diagnosis of the mental disorder.
4.Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K1, Ogawa C2,3, Okamoto Y4, Kudo K5,6, Inagaki J7, Morimoto T8, Mizukami H9, Ecstein-Fraisse E9, Kikuta A10. Int J Hematol. 2016 Apr 16. [Epub ahead of print]
A phase 1 study was conducted to evaluate the safety, pharmacokinetics (PK), efficacy and pharmacogenetic characteristics of clofarabine in seven Japanese pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Patients in Cohort 1 received clofarabine 30 mg/m2/day for 5 days, followed by 52 mg/m2/day for 5 days in subsequent cycles. Cohort 2 patients were consistently treated with 52 mg/m2/day for 5 days. No more than six cycles were performed. Every patient had at least one ≥Grade 3 adverse event (AE). AEs (≥Grade 3) related to clofarabine were anaemia, neutropenia, febrile neutropenia, thrombocytopenia, alanine aminotransferase increased, aspartate aminotransferase increased, haemoglobin decreased, and platelet (PLT) count decreased. C max and AUC of clofarabine increased in a dose-dependent fashion, but its elimination half-life (T 1/2) did not appear to be dependent on dose or duration of treatment. Clofarabine at 52 mg/m2/day shows similarly tolerable safety and PK profiles compared to those in previous studies.